The incidence, predictive, and prognostic impact of programmed cell death (PD‐L1) expression in gastric (GC) and gastroesophageal junction tumors (GEJC) treated with perioperative chemotherapy is poorly understood. We aimed to… Click to show full abstract
The incidence, predictive, and prognostic impact of programmed cell death (PD‐L1) expression in gastric (GC) and gastroesophageal junction tumors (GEJC) treated with perioperative chemotherapy is poorly understood. We aimed to assess PD‐L1 expression by immunohistochemistry (IHC) in both pre and posttreatment specimens evaluating its impact on pathological response and survival outcomes.
               
Click one of the above tabs to view related content.